# Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma

> **NCT02605421** · PHASE2 · RECRUITING · sponsor: **Masonic Cancer Center, University of Minnesota** · enrollment: 12 (estimated)

## Conditions studied

- Neuroblastoma

## Interventions

- **DRUG:** Thiotepa
- **DRUG:** Cyclophosphamide
- **DRUG:** Melphalan
- **DRUG:** Etoposide
- **DRUG:** Carboplatin
- **BIOLOGICAL:** Autologous Stem Cell Infusion
- **BIOLOGICAL:** Granulocyte colony stimulating factor

## Key facts

- **NCT ID:** NCT02605421
- **Lead sponsor:** Masonic Cancer Center, University of Minnesota
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2016-06
- **Primary completion:** 2026-10-01
- **Final completion:** 2026-12
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2025-10-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02605421

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02605421, "Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma". Retrieved via AI Analytics 2026-07-07 from https://api.ai-analytics.org/clinical/NCT02605421. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*